

Index

A

- Academy of Managed Care Pharmacy (AMCP)
 - evidence requirements 186
- accelerated filings
 - ancillary activity considerations with 248–252
 - ANVISA initiatives for 250–252
 - communication with FDA 246–252
 - compassionate use/single patient IND 248–252
 - COVID-19 pandemic and 251
 - expanded access 246
 - FDA initiatives 245–252
 - HDE and 248
 - rolling reviews for 246–252
 - state-level “Right to Try” laws 249
 - surrogate endpoint use 249
- Advisory Committee (AC) Meetings
 - NDA review and approval 60
 - review and approval process 62
- Agencia Nacional de Vigilancia Sanitaria (ANVISA) Initiatives 250
- annual product review updates 180
- artificial intelligence (AI) in regulatory writing 10
- audience requirements
 - for CSR 99
 - for labeling 151–154
 - for value dossiers 185
 - integrated nonclinical discussions 121
 - labeling for globalization 152–154
 - labeling for nontechnical 151–154
 - regulatory versus publication writing 253

B

- background packages
 - draft briefing package for EU 165–166
 - FDA meeting package content and format 162–164
 - FDA meeting request content and format 161–164
 - final briefing package for EU 165–166
 - for scientific advice and protocol assistance 164–169
 - medical device meetings 166
 - pre-submission meeting 165–166
 - Q-Submission package 167–169
 - submission and meeting feedback 167–169
 - submission process 165–166
 - submission process for FDA 163–164
 - US pharmaceutical and biologics 159
- Belmont Report 79, 79–87, 95
- Bioresearch Monitoring (BIMO) protocol violations 74
- biosimilars
 - analytical similarity demonstration 206
 - animal studies for evaluation 207
 - clinical considerations for 207
 - comparability versus biosimilarity 209
 - development process for 205–213
 - efficacy and safety of 208
 - extrapolation of indications 208
 - geographic jurisdiction for 209

- immunogenicity assessment for 208
- interchangeability 209
- labeling of 210
- naming and pharmacovigilance for 210
- pharmacokinetics and pharmacodynamics 208
- regulation of generics 196
- stakeholder education 211–213
- versus generics 203–213

Biosimilars Action Plan (BAP) 211

biotechnology-derived products 193

C

Centralised Procedure 173

chemistry, manufacturing and controls (CMC) 111

- documentation for 111
- format and content of documentation 112–114
- lifecycle management of documentation 114
- preparing documentation for 113–114
- regional information for 114

Clinical and Laboratory Standards Institute (CLSI) 31

clinical study report (CSR)

- changes to 108–109
- content of 99–109
- finalization and notification 107–109
- guidance for 99–109
- ICH requirements for 103–109
- narratives for 105
- planning meeting for 102–109
- preparation 106–109
- publication writing and 256
- public disclosure of 107
- redaction for disclosure 107
- requirements for appendices 103–109
- results review 106–109
- shell preparation 105–109
- single study with multiple 108–109
- source materials for 100–109
- timelines and milestones for 103–109
- types of 100–109
- writing and reviewing of 105
- writing conventions 105–109

clinical study results. See lay summaries of study results

Clinical Summary

- content of 136
- in integrated clinical documentation 130
- ISE/ISS relationship to 140

clinical trial protocols

- amendments to 75–77
- development of 72–77
- endpoint for study 74
- ethical requirements for 71–77
- for biosimilars 208
- for publication and peer review 76
- key elements of 73–77
- population and methodology 74
- protocol synopsis 72
- registration of trial 76–77
- regulatory agency requirements 72–77
- safety and reporting requirements 74–77
- sponsor and funding agency roles 72–77
- statistical analysis plan 75–77
- study design and methodology 73–77
- study endpoint definitions 74
- templates for 73–77
- violations of 74

ClinicalTrials.gov 95

Code of Federal Regulations

- integrated summary requirements for 138
- writing guidance in 30

Code of Federal Regulations (CFR)

- combination product requirements 216–223
- Federal Register history and use 29–40
- informed consent regulations 79
- regulatory writing requirements for 29
- safety update reporting 142

combination product design and development

- categorization of constituent parts 218–219
- CGMP requirements for 216–223
- constituents with prior marketing approval 218–223
- definition of product 215–223
- general recommendations for 221–223
- human factors application to 220–223
- IND applications and 220–223
- pivotal clinical study use of device 221–223
- risk management for 219–223
- special regulatory considerations 217–218

Common Technical Document (CTD)

- clinical sections of 131–137
- CMC information in 111
- information assembly and 18
- information presentation in 25
- marketing application format 57
- modular structure in 25–27

Company Core Data Sheet (CCDS) 181

complete response letter (CRL) 172
CONSORT 96, 254
contract research organization (CRO) 72
COVID-19 public health emergency
 accelerated approval pathways due to 251
 adjustments to CSRs 108–109
 conducting clinical studies in 126
 effects on SAPs 90
 FDA requests for information and 171
 ICF requirement with 85–87
 impact on clinical trials 75–77
 medical device submissions and 41–43
 new vaccine and biologic guidelines for 190
 orphan designations and 235
 pharmaceutical industry impact of 145–149
 statistical guidance with 89

D

data analysis plans
 clinical trial ethics and transparency in 95–98
 data collection and handling quality for 93–98
 data handling for trials 94–98
 data-handling methods in therapeutic area 96
 guidance document updates 89–98
 ICH E9 content for 90–98
 SAP development 96–98
 scope of SAPs 93
 study reporting requirements 94–98
 therapeutic area statistical analysis 95
 writing statistical analysis plan 90–98
Decentralised Procedure 173
Declaration of conformity, updating 181
Declaration of Geneva 79
Declaration of Helsinki 71, 76, 79, 94, 95
Development International Birth Date (DIBD) 148
Development Safety Update Report (DSUR) 181
discipline review 171
document inventory lists 18
dossier maintenance 179
 annual reports for 182–184
 clinical safety update 181
 consequences of maintenance failure 183–184
 documents requiring maintenance 180–184
 identification of requirements 179–184
Drug Master Files, updating 180

E

endpoints
 accelerated filings and 249–252

 biomarkers and 249
 in lay summaries 271
 surrogate 249
EQUATOR network 96, 254
ethical requirements
 in clinical trials 71–77
 transparency of trial results 95
EudraCT 95
EU Marketing Authorization Application (MAA)
) 63–70
 Centralised Procedure timeline for 66
 overview of review process 65
EU medicinal products
 background packages for meetings 164
European Federation of Good Clinical Practice
 (EFGCP) 271
European Federation of Pharmaceutical Industries
 Association (EFPIA) 271
European Federation of Pharmaceutical Industries
 (EfPIA) 107
European Medicines Agency (EMA)
 accelerated approval pathways 249–252
 COVID-19 impact on clinical trials 90
 data monitor committee checklist 89
 guidance on EU requirements 30
 medical device regulatory framework 31–40
 PIP requirements 237
 PIP submissions 241
 protocol assistance 72
 rare disease definition 225
European Union (EU)
 comment or information requests from 172–
 173
 General Data Protection Regulation 85–87
 interventional trial information 76
 lay summaries regulatory requirements 266–
 275
 regulatory pathways in 173–174
 scientific advice and protocol assistance
 meetings 164
expanded access (compassionate use), IND for 192
expedited reporting, IB contents and 145

F

first-in-human study, nonclinical data for 74
Food and Drug Administration (FDA)
 adoption of ICH recommendations 29
 application review by 6
 Biosimilars Action Plan 211

- Clinical Summary replacement for ISS/ISE 130
- COVID-19 guidance from 126
- COVID-19 impact on clinical trials 90, 146
- CSR guidance 100
- formal meetings 160–164
- guidance for industry 31–40
- IFC development 80
- medical device regulatory framework 31–40
- meeting types and purposes 160–169
- New Drug Application (NDA) review 59–70
- orphan drug designation request 225
- rare disease definition 225
- regulations pertaining to 29
- Special Protocol Assessment 72
- support for master protocols 75
- trial registration 76
- types of formal meetings with 160–169
- Formal Communication Plan 59
- formatting/format
 - importance of 25–27
 - nonclinical reports 118–124
- Form FDA 483 observations for GDPs 20–22

G

- General Data Protection Regulation (EU) 85
- General Safety and Performance Requirements, updating 181
- Good Clinical Practice (GCP)
 - Investigator’s Brochure requirement 145
 - statistical analyses in 95
- Good Documentation Practices (GDPs)
 - 21 CFR good practices resources 39
 - basic principles for 16–22
 - consistency, clarity, completeness in 17
 - creating a system for 20–22, 21–22
 - documenting procedures 17–22
 - for SAPs 94–98
 - goals of documentation 16–22
 - guidelines and resources for 18–22
 - overview of 15
 - principles and development of 15
 - transparency and disclosure in 18
- guidance documents and resources
 - identifying guidelines 18–22
 - professional societies 40
 - sources for 38–40

H

- health technology assessments (HTAs). See value dossiers
- humanitarian device exemption (HDE)
 - HUD marketing 234
- Humanitarian Device Exemption (HDE)
 - accelerated filings for 248
- Humanitarian Use Device (HUD)
 - HDE application for 248
 - requests for 234

I

- Independent Monitoring Committee (IDMC) 74
- individual study reports 199
- information request letter 172
- informed consent form (ICF)
 - audience considerations for 82–87
 - development of 84–87
 - history and purpose of 79–87
 - information provided in 80–87
 - in protocol development 83–87
 - scope of clinical activity 83–87
 - sponsor requirements for 83–87
 - updates to 83
- Integrated Summary of Safety (ISS) 138
- integrated clinical documentation
 - attention to regulations and guidelines in 127–143
 - benefit and risk conclusions 135
 - Clinical Overview 132
 - Clinical Summary 136
 - CTD clinical sections 131
 - CTD format in 131–132
 - goals for 126–143
 - guidance and updates with COVID-19 125–143
 - ICH guideline updates on clinical documentation 126–143
 - integrated data discussions 126–143
 - Integrated Summary of Efficacy in 138
 - Integrated Summary of Safety in 140
 - lifecycle management of documentation 129
 - maintaining consistency in 127–143
 - medical writers role in 131–132
 - Module 5 137
 - multiple clinical trial comparisons 125–143
 - post-approval summaries at marketing application 129–143

- regulatory documents in 129–132
 - safety update reporting 142
 - systematic approach for consistency 128–143
 - tables included in studies 138
 - transparency in data from trials 128–143
 - US requirements for 138
 - integrated CMC documentation. See chemistry, manufacturing and controls (CMC)
 - integrated nonclinical documentation
 - authoring discussions in 121–124
 - CTD safety structure 120–124
 - discussions of 119–124
 - electronic publishing readiness 118–124
 - for biologics 197
 - overview format and content 120–124
 - qualities of 115–124
 - study reports 117–124
 - style guides for 119
 - written and tabulated summaries for 121–124
 - Integrated Summary of Efficacy (ISE) 138
 - Integrated Summary of Safety (ISS) 129, 140
 - interdisciplinary documents. See dossier maintenance
 - International Committee of Medical Journal Editors (ICMJE) criteria 254–258
 - International Council for Harmonisation for Technical Requirements for Pharmaceuticals for Human Use (ICH) 29
 - International Council for Harmonisation (ICH) harmonized submissions 7
 - International Council on Harmonisation (ICH)
 - CSR requirements for appendices 103–109
 - drug substance documentation 112–114
 - estimand and sensitivity analysis 89
 - guidelines from 31–40
 - guidelines on CSR 99
 - harmonized submission evolution 12–13
 - IFC development guidance 80
 - Investigator's Brochure requirement 145
 - nonclinical format and content 120–124
 - scope of biotechnology-derived products 193
 - species specificity of biologics 197
 - statistical plan guidance 75, 90
 - International Medical Device Regulators Forum (IMDRF) Table of Contents structure 25
 - International Organization for Standardization (ISO) 31
 - Interventional Study 74
 - Invented Name Review 63
 - Investigational Medicinal Product Dossier (IMPD) 145
 - Investigational New Drug (IND) submission
 - Investigator's Brochure for 145
 - protocol review 72
 - Investigator's Brochure (IB)
 - content contributors for 146
 - content development for 146–149
 - contents of 145
 - essential components of 146–149
 - purpose of 145–149
 - updates to 148–149
 - with multiple product indications 148
- K**
- key opinion leaders (KOLs) 72
- L**
- labeling
 - audience requirements for 151–154
 - consequence statement 156
 - draft review 61
 - general content principles 154
 - hazard description for 156
 - IB content and 145
 - of biosimilars 210
 - prevention measures in 156
 - regulatory sources for 156–157
 - risk control measures for 154
 - risk statement content and layout 154
 - risk statements in 154
 - standards for 157
 - symbols, colors and codes in 153–154
 - updating 180
 - writing for global audience 152–154
 - writing for nontechnical audience 151–154
 - lay summaries of study results 265
 - development of 273
 - endpoint inclusion in 271
 - EU CTR requirements for 266
 - European expert group recommendations 266–275
 - for children 272
 - good practices for 270
 - implementation guide for 270–275
 - MRCT guidance document 267–275
 - non-promotional language for 269–275
 - studies in healthy volunteers 272–275

lifecycle management
 CMC documentation 114
 integrated clinical documentation 129
 integrated nonclinical documentation 122
 Investigator's Brochure 148–149
 updating documents 179

literature reviews
 information sources 261–263
 narrative (non-systematic) and systematic 259–263
 reporting and methodological guidelines 260–263
 search strategies for 262–263

M

master protocol, for clinical trials 75–77
MedDRA 94
medical device submissions
 background packages for 166–168
 considerations for writing 41–43
 refuse to accept notification 172
 regional requirements for 42–43
 regulatory framework for 31–35

Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines 260

Multi-Regional Clinical Trial (MRCT) working group 265

Mutual Recognition Procedure 173

N

National Cancer Institute (NCI), protocol templates 73

National Research Act 79

New Chemical Entity (NCE), development process 111

New Drug Application (NDA)
 filing and review timeline 59–70
 Formal Communication Plan 59–70
 preapproval inspections 62–70
 prescribing information draft 62–70
 Proprietary Name Review 61–70
 review and approval process 59–70
 review process and milestones 60–70

New Molecular Entity's (NME), development process for 111

Notification of Clinical Hold 172

Nuremberg Code 79–87

O

Observational Study 74

Office of Orphan Products Development (OOPD) 225

orphan designation/rare diseases
 accelerated review for 248
 business benefits from 226
 clinical superiority demonstration 231
 criteria for 225
 criteria in EU 249
 humanitarian use devices 234–236
 In FDA versus EU 226
 in US 226–236
 orphan designation for 225
 pediatric priority review for 231
 preparing request for designation 229–236
 regulatory definition of 225
 resources for 231
 Special Protocol Assessment for 72
 supporting evidence for designation 229–236

P

Parent Consent for Child to Act as a Research Subject" form 83

Patient-Reported Outcomes (PROs) 271

Pediatric Investigational Plan (PIP)
 compliance check for 242–243
 contents of 239–243
 development of 238–243
 legal framework for 237–243
 modifying agreed plan 241–243
 notification of discontinuation 242–243
 submission process for 241–243

Periodic Benefit-Risk Evaluation Report (PBRER) 181

Periodic Safety Update Report (PSUR) 181

Pharmaceutical Research and Manufacturers of America (PhRMA)
 code of ethics 95
 data sharing principles 107
 guidance and ethical code 31

Plain Language Summary (PLS) 265

planning and strategy documents (PSDs)
 definition of 46
 development of 46
 for regulatory submissions 46–55

Post Market Surveillance Report (PMSR) 181

preapproval Inspections 62

Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) 260
Prescribing Information (PI), development of 62
professional societies, guidelines from 40
Proprietary Name Review (PNR) 61–70
Protocol Review Committee. 72
publication
 clinical trial data disclosure and transparency in 255
 good publication practice (GPP) guidelines 253
 investigator's roles and responsibilities in 254
 planning for 253
 protocol submission for 76–77
 regulatory versus publication writing 253
 SAP for 90
 statistical analyses for 96

Q

Quality Assessment tool of Diagnostic Accuracy Studies (QUADAS) 260
Quality Management Systems (QMS) 17
Quality of Reporting of Meta-analyses (QUOROM) Statement. 260
questions/requests for information
 FDA communication with sponsors 171
 from EU regulatory authorities 172–173
 preparation and planning for 57–70
 written responses to 174

R

rare pediatric disease designation 233–236
Recommendation for Interventional Trials (SPIRIT) 73
Reference Safety Information for Assessment of Expectedness of Serious Adverse Reactions 145
refuse to accept hold notifications 172
regulatory writing
 audience needs in 24–27
 audiences for writing 2
 automated redaction, translation and big data summaries 278–280
 barriers to effective communication in 23–27
 before harmonization 3
 changes in audience for 9
 comprehension aids for 26–27
 design for comprehension 25–27
 documents produced by 2
 document type and development stage 25–27

 editing of 26
 format in 25–27
 harmonized submissions 7
 key information presentation 25–27
 plain language in 26–27
 structured content management 278–280
 submission procedure changes and 6
 teamwork 23
 technology impact on 4
 written content as data 277
reporting requirements 74–77
review and approval process
 CTD for submission 57–70
 EU Marketing Authorization Application 63–70
 New Drug Application 59–70
 preparation for information requests 57–70
risk management, updating 181
risk statements
 content and layout 154–157
 in labeling 154
 labeling risk control measures 154
rolling reviews 246

S

Safety Update Reporting 142
signal word in labeling 154
solicited reports, updating 182
SPIRIT checklist 255
standard operating procedures (SOPs)
 defined 46
 development of 46, 46–55
 importance of 45, 45–55
 in integrated discussions 123
 regional differences for 54–55
 scope of 47–55
 updating 40
 updating of 181
statistical analysis plans (SAPs)
 collaboration for 96–98
 elements of 93–98
 endpoint analysis 74
 for publications 96
 guidelines for 96
 ICH E9 content overview 90–98
 in clinical trial protocol 75–77
 rationale for 90–98
 reporting requirement in 94

- style guides
 - clinical study reports 105
 - integrated nonclinical documentation 123
- Summary of Data and Guidance for the Investigator 145
- surrogate endpoints 249
- Suspected Unexpected Serious Adverse Reactions (SUSARs)
 - reporting timeline 74

T

- TransCelerate
 - guidance for submissions 31
 - harmonization for CSR disclosure 107
 - implementation guide 270
 - layperson summary 265
 - non-promotional language guidance 269
 - non-promotional language guidance and recommendations 269
 - non-promotional language recommendations 269
 - template from 73
- transparency and disclosure for GDPs 18

U

- United States (US)
 - biologics regulation 193–201
 - NDA/BLA milestones 61
 - returning study results to participants 266–275

V

- vaccines and biologics
 - biologics definitions 192
 - expanded access for 246–252
 - guidance updates and adjusted definitions for 189
 - integrated documentation 199
 - regulation of biologics 193
 - regulatory documentation for 198–201
 - special documentation for vaccines 198–201
 - specialized content for documents 189
 - therapeutic areas for 197–201
 - therapeutic areas of 197
 - vaccine subset 193
- value dossiers
 - audience for 185
 - compilation of 188
 - purpose of 185
 - regional differences and format of 186–188
 - resources for writing 188

W

- WHO-DDE 94
- World Health Organization (WHO) 31
- written responses to questions/information requests
 - best practices for preparing 174
 - content and organization of 174
 - timing 176